药品注册申请号:070918
申请类型:ANDA (仿制药申请)
申请人:HOSPIRA
申请人全名:HOSPIRA INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 NALBUPHINE HYDROCHLORIDE NALBUPHINE HYDROCHLORIDE SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 200MG/10ML (20MG/ML) No Yes AP 1989/02/03 1989/02/03 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
审批日期提交号审批结论提交分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
1989/02/03 ORIG-1(原始申请) Approval
>>>补充申请<<<
审批日期提交号审批结论补充类别或审批类型审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/08/27 SUPPL-36(补充) Approval Labeling-Package Insert STANDARD
2023/12/15 SUPPL-34(补充) Approval Labeling-Package Insert STANDARD
2023/12/01 SUPPL-29(补充) Approval Labeling-Package Insert STANDARD
2019/10/16 SUPPL-28(补充) Approval Labeling-Package Insert STANDARD
2016/12/16 SUPPL-26(补充) Approval Labeling-Package Insert,Labeling-Medication Guide STANDARD
2016/12/16 SUPPL-25(补充) Approval Labeling-Package Insert STANDARD
2007/11/30 SUPPL-18(补充) Approval Labeling
2002/10/25 SUPPL-14(补充) Approval Manufacturing (CMC)-Microbiology-Processing
1999/07/12 SUPPL-13(补充) Approval Manufacturing (CMC)
1998/05/05 SUPPL-12(补充) Approval Manufacturing (CMC)-Microbiology-Processing
1997/02/27 SUPPL-11(补充) Approval Manufacturing (CMC)
1997/02/27 SUPPL-10(补充) Approval Manufacturing (CMC)
1997/02/27 SUPPL-9(补充) Approval Manufacturing (CMC)
1996/10/03 SUPPL-8(补充) Approval Manufacturing (CMC)-Microbiology-Processing
1996/04/26 SUPPL-5(补充) Approval Labeling
1991/02/28 SUPPL-3(补充) Approval Labeling
1990/07/25 SUPPL-2(补充) Approval Labeling
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
>>>活性成分:NALBUPHINE HYDROCHLORIDE; 剂型/给药途径:SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; 规格:200MG/10ML (20MG/ML); 治疗等效代码:AP<<<
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
070918 001 ANDA NALBUPHINE HYDROCHLORIDE NALBUPHINE HYDROCHLORIDE SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 200MG/10ML (20MG/ML) Prescription No Yes AP 1989/02/03 HOSPIRA
216049 002 ANDA NALBUPHINE HYDROCHLORIDE NALBUPHINE HYDROCHLORIDE SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 200MG/10ML (20MG/ML) Prescription No No AP 2024/09/19 SOMERSET THERAPS LLC
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2025 DrugFuture->U.S. FDA Drugs Database